Live Breaking News & Updates on Fn Beta

Stay updated with breaking news from Fn beta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First-Line Highly Effective Therapy Better for Pediatric MS

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis. ....

Department Of Pediatric Neurology , University Angers , Expanded Disability Status Scale , Nail Benallegue , Pediatric Neurology , Multiple Sclerosis Ms , S Multiple Sclerosis , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Glatiramer Acetate , Interferon Beta , Fn Beta , Interferon Beta , Monoclonal Antibody ,

Emerging Therapies Foretell New Era for Cutaneous Disorders

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders. ....

United States , Anthony Fernandez , Drug Administration , American Academy Of Dermatology , Cleveland Clinic , Cutaneous Lupus Erythematosus Disease Area , Severity Index , Cutaneous Dermatomyositis Disease Area , New England Journal , American Academy , Systemic Lupus Erythematosus Sle Erythaematosus , Cutaneous Lupus Erythematosus Erythaematosus , Biologic Therapy , Interferon Beta , Fn Beta , Interferon Beta , Monoclonal Antibody , Multiple Sclerosis Ms , S Multiple Sclerosis , Clinical Research ,

A New Clue Into the Cause, Spread of Parkinson's Disease?

Damaged mitochondrial DNA initiates and spreads Parkinson s disease pathology, potentially opening new avenues for early diagnosis, researchers say. ....

James Beck , Shohreh Issazadeh Navikas , Parkinson Foundation , University Of Copenhagen , Medscape Medical , Medscape Medical News , Parkinsons Disease , Oxidative Stress , Nerve Cell , Cognitive Impairment , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Drug Development , Mild Cognitive Impairment , Iological Marker , Interferon Beta , Fn Beta , Medical Innovations , Nnovations In Medicine ,

Data Support Interferon Beta as Therapeutic Target

Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial. ....

United States , Hensin Tsao , Paul Nghiem , Aaron Mangold , University Of Washington , American Academy Of Dermatology , Lesion Center At Massachusetts , American Academy , Mayo Clinic , Cutaneous Dermatomyositis Disease Area , Severity Index , Pigmented Lesion Center , Massachusetts General Hospital , Biologic Therapy , Interferon Beta , Fn Beta , Skeletal Myoblasts , Skeletal Muscle , Disease Modifying Antirheumatic Drugs Dmards , Mard Disease Modifying Antirheumatic Drug , Herpes Zoster , Malignant Melanoma , Monoclonal Antibody ,

Despite Challenges, Experts Optimistic About MS Therapy's Future

Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say that s both a blessing and problem. ....

New York , United States , Mark Gudesblatt , Fredd Lublin , Shore Neurologic Associates In Patchogue , Drug Administration , Ms Care Center , Corinne Goldsmith Dickinson Center , Multiple Sclerosis , Mount Sinai , South Shore Neurologic Associates , Multiple Sclerosis Ms , Multiple Sclerosis , Interferon Beta , Fn Beta , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Cognitive Impairment , Genetic Disorder , Biologic Therapy , Disease Modifying Therapy , Glatiramer Acetate , Movement Disorder , Young Adult ,